Response Genetics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the third quarter, the company reported the revenue of $2,259,523 and net loss of $1,972,870 or basic and diluted earnings per share of $0.14 compared to the revenue of $1,957,030 and net loss of $2,195,717 or basic and diluted earnings per share of $0.21 for the same period a year ago. Operating loss was $1,970,766 compared to the operating loss of $2,269,480 for the same period a year ago. For the nine months, the company reported the revenue of $5,694,988 and net loss of $7,618,231 or basic and diluted earnings per share of $0.60 compared to the revenue of $5,683,409 and net loss of $6,092,436 or basic and diluted earnings per share of $0.60 for the same period a year ago. Operating loss was $7,632,189 compared to the operating loss of $6,405,100 for the same period a year ago.

Response Genetics, Inc expected to Report Fiscal Year 2009 Results on March 26, 2010. This event was calculated by Capital IQ (Created on November 13, 2009).

Response Genetics Inc. announced the availability of its ResponseDX: Gastric genetic test panel a proprietary PCR-based diagnostic test. By analyzing the expression of genes that correlate with response to commonly used chemotherapy agents, physicians can better tailor treatment for their patients with gastric cancer and gastroesophageal junction cancer. Approximately 37,000 people diagnosed with cancer each year in the U.S. may benefit from ResponseDX: Gastric testing.